Login to Your Account

Investors 'ZEALous' as Sanofi phase III data keep Lixilan filing on track

By Cormac Sheridan
Staff Writer

Monday, September 14, 2015
DUBLIN – Sanofi SA remains on track to complete a fourth-quarter regulatory submission of Lixilan, a fixed-ratio combination of its basal insulin (Lantus; insulin glargine) and its glucagon-like peptide 1 (GLP-1) receptor agonist Lyxumia (lixisenatide), on the back of a positive readout from the second of two phase III trials in type 2 diabetes patients.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription